BioPharmSignal logoBioPharmSignal

Biotech News

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical (RARE)Ultragenyx PharmaceuticalEarnings

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 3, 2026, to discuss its financial results and corporate update for the quarter ending September 30, 2026.

Related news

RAREUltragenyx Pharmaceutical2026-07-28 20:05 EST

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

RAREUltragenyx Pharmaceutical2026-08-04 20:05 EST

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

CAPRCapricor Therapeutics2026-11-03 14:00 EST

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

PTCTPTC Therapeutics, Inc.2026-10-29 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

AGIOAgios Pharmaceuticals, Inc.2026-10-08 11:00 EST

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

CAPRCapricor Therapeutics2026-08-13 20:05 EST

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PTCTPTC Therapeutics, Inc.2026-07-30 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

TARAProtara Therapeutics2026-11-06 13:00 EST

Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ETONEton Pharmaceuticals2026-10-29 10:50 EST

Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

View all latest news

Ultragenyx Pharmaceutical

Rare-Disease Portfolio Ultragenyx Pharmaceutical develops and commercializes therapies for serious rare and ultrarare genetic diseases. Its portfolio spans antisense oligonucleotides, enzyme and small-molecule medicines, and adeno-associated virus gene therapies. GTX-102 for Angelman Syndrome GTX-102, or apazunersen, is an antisense...

Recent company news

RAREUltragenyx Pharmaceutical2026-11-06 08:30 EST

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

RAREUltragenyx Pharmaceutical2026-10-27 20:05 EST

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

RAREUltragenyx Pharmaceutical2026-10-14 12:30 EST

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

RAREUltragenyx Pharmaceutical2026-10-07 12:30 EST

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

RAREUltragenyx Pharmaceutical2026-10-02 06:00 EST

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

Stock data

Close
15.57 USD
Market cap
2.15B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States